FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591635950> ?p ?o ?g. }

• W2591635950 abstract "Abstract As a novel approach to primary treatment of aggressive lymphoma, we tested the feasibility and efficacy of a four cycle high-dose chemotherapy protocol including autologous stem cell transplantation after cycles 2, 3 and 4. In a multicenter Phase II study patients with newly diagnosed aggressive NHL, age between 18–60 years, and LDH > N at diagnosis were included. At dose level 1, cycle 1 consisted of Cyclophosphamide (CY) 1500 mg/m2, Adriamycin (ADR) 70 mg/m2, Vincristine 2mg, Etoposide (ETO) 450 mg/m2, and Prednisone 500 mg/m2. In subsequent cycles doses of CY and ETO were increased: Cycle II and III : CY 4500 mg/m2 and ETO 600mg/m2, cycle IV: CY 6000 mg/m2 and ETO 1000 mg/m2. At dose level 2 ETO was further increased throughout all cycles to 600, 960, 960 and 1480 mg/m2, respectively. From February 97 to August 99, 124 patients were enrolled 14 patients had to be excluded mostly due to correction of initial diagnosis. 110 patients were evaluable with a median observation time of 55 months. 81.8% of patients completed therapy as per protocol. There were 5 cases of treatment related mortality (4.5%), and one of these deaths was due to secondary leukemia (0.9%). Overall survival at 5 years was 67.2 % and freedom from treatment failure was 62.1 %. The following factors were tested with respect to their impact on time to treatment failure (TTTF): age, sex, extranodal disease, bulky disease, performance status, B-symptoms, stage, age-adjusted IPI and LDH. In univariate analysis, only the risk factors of the age-adjusted IPI and IPI itself showed a significant impact on TTTF: see table 1. In a Cox regression multivariate analysis, LDH remained the only independent risk factor with a relative risk of 2.0 (p=0.046). Mega-CHOEP is feasible and effective treatment in younger pts. with aggressive lymphoma. Elevated LDH has major prognostic significance in patients receiving repetitive high-dose therapy and autologous stem cell transplantation. A phase III study comparing Mega-CHOEP + Rituximab to conventional chemotherapy in younger pts. with aggressive NHL is ongoing. Table 1 Risk factor 2-years TTTF p-value LDH (< 2xONV/> 2xONV) 73.1 vs 48.2% p=0.004 Stage (I, II/III, IV) 76.5 vs 60.9% p=0.044 Performance status (ECOG 0, 1/>1) 73.2 vs 51.2% p=0.047 Age-adjusted IPI (1, 2/3) 72.4 vs 45.4% p=0.007" @default.
• W2591635950 created "2017-03-16" @default.
• W2591635950 creator A5002498295 @default.
• W2591635950 creator A5009186146 @default.
• W2591635950 creator A5014979722 @default.
• W2591635950 creator A5025105470 @default.
• W2591635950 creator A5029063148 @default.
• W2591635950 creator A5036867361 @default.
• W2591635950 creator A5039235274 @default.
• W2591635950 creator A5045752653 @default.
• W2591635950 creator A5071228709 @default.
• W2591635950 date "2004-11-16" @default.
• W2591635950 modified "2023-10-12" @default.
• W2591635950 title "Repetitive High-Dose Therapy with Dose Escalated CHOP + Etoposide Followed by Autologous Stem Cell Transplantation (Mega-CHOEP) in Younger Patients with Primary Diagnosis of Aggressive NHL and Elevated LDH at Diagnosis: Final Analysis." @default.
• W2591635950 doi "https://doi.org/10.1182/blood.v104.11.610.610" @default.
• W2591635950 hasPublicationYear "2004" @default.
• W2591635950 type Work @default.
• W2591635950 sameAs 2591635950 @default.
• W2591635950 citedByCount "2" @default.
• W2591635950 crossrefType "journal-article" @default.
• W2591635950 hasAuthorship W2591635950A5002498295 @default.
• W2591635950 hasAuthorship W2591635950A5009186146 @default.
• W2591635950 hasAuthorship W2591635950A5014979722 @default.
• W2591635950 hasAuthorship W2591635950A5025105470 @default.
• W2591635950 hasAuthorship W2591635950A5029063148 @default.
• W2591635950 hasAuthorship W2591635950A5036867361 @default.
• W2591635950 hasAuthorship W2591635950A5039235274 @default.
• W2591635950 hasAuthorship W2591635950A5045752653 @default.
• W2591635950 hasAuthorship W2591635950A5071228709 @default.
• W2591635950 hasConcept C126322002 @default.
• W2591635950 hasConcept C141071460 @default.
• W2591635950 hasConcept C2776694085 @default.
• W2591635950 hasConcept C2776755627 @default.
• W2591635950 hasConcept C2776907518 @default.
• W2591635950 hasConcept C2778119113 @default.
• W2591635950 hasConcept C2778476033 @default.
• W2591635950 hasConcept C2778720950 @default.
• W2591635950 hasConcept C2778822529 @default.
• W2591635950 hasConcept C2779050716 @default.
• W2591635950 hasConcept C2779429289 @default.
• W2591635950 hasConcept C2911091166 @default.
• W2591635950 hasConcept C71924100 @default.
• W2591635950 hasConcept C90924648 @default.
• W2591635950 hasConceptScore W2591635950C126322002 @default.
• W2591635950 hasConceptScore W2591635950C141071460 @default.
• W2591635950 hasConceptScore W2591635950C2776694085 @default.
• W2591635950 hasConceptScore W2591635950C2776755627 @default.
• W2591635950 hasConceptScore W2591635950C2776907518 @default.
• W2591635950 hasConceptScore W2591635950C2778119113 @default.
• W2591635950 hasConceptScore W2591635950C2778476033 @default.
• W2591635950 hasConceptScore W2591635950C2778720950 @default.
• W2591635950 hasConceptScore W2591635950C2778822529 @default.
• W2591635950 hasConceptScore W2591635950C2779050716 @default.
• W2591635950 hasConceptScore W2591635950C2779429289 @default.
• W2591635950 hasConceptScore W2591635950C2911091166 @default.
• W2591635950 hasConceptScore W2591635950C71924100 @default.
• W2591635950 hasConceptScore W2591635950C90924648 @default.
• W2591635950 hasLocation W25916359501 @default.
• W2591635950 hasOpenAccess W2591635950 @default.
• W2591635950 hasPrimaryLocation W25916359501 @default.
• W2591635950 hasRelatedWork W1969994327 @default.
• W2591635950 hasRelatedWork W1971536278 @default.
• W2591635950 hasRelatedWork W2026096307 @default.
• W2591635950 hasRelatedWork W2114602553 @default.
• W2591635950 hasRelatedWork W2146456594 @default.
• W2591635950 hasRelatedWork W2150420937 @default.
• W2591635950 hasRelatedWork W2168662263 @default.
• W2591635950 hasRelatedWork W2183352065 @default.
• W2591635950 hasRelatedWork W2418028115 @default.
• W2591635950 hasRelatedWork W2591635950 @default.
• W2591635950 isParatext "false" @default.
• W2591635950 isRetracted "false" @default.
• W2591635950 magId "2591635950" @default.
• W2591635950 workType "article" @default.